BioPharmSignal logoBioPharmSignal

Biotech News

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.2026-06-25 13:46 ESTEarnings

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment of Chris Murphy as CFO Announced appointments of Susannah Gray, former CFO

Open original release

Related news

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Announces Participation at Upcoming Investor Conferences

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

View all latest news

AnaptysBio, Inc.

AnaptysBio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANABAnaptysBio, Inc.2026-06-26 02:33 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-06-26 02:33 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-06-26 02:33 EST

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANABAnaptysBio, Inc.2026-06-26 02:33 EST

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

ANABAnaptysBio, Inc.2026-06-26 02:33 EST

Anaptys Announces Participation at Upcoming Investor Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States